IE 11 is not supported. For an optimal experience visit our site on another browser.
  • UP NEXT

    Meet the female founders transforming the tequila industry

    05:15
  • March Madness: Steve Kornacki breaks down the Sweet 16 games

    04:39
  • Erin Andrews and Kristen Welker share stories of infertility

    07:24
  • Former Sen. Joe Lieberman dies at 82: ‘A man of integrity’

    00:29
  • Americans trapped in Haiti grow more desperate to flee

    01:59
  • Search continues for $1.13B Mega Millions lottery winner

    02:36
  • Why Dollar Tree is raising prices as high as $7

    02:52
  • Growing number of women report being punched on NYC streets

    02:49
  • What can travelers expect with spring break, Easter and eclipse?

    01:31
  • ‘Senseless’: Man accused of fatally stabbing 4 people in Illinois

    00:25
  • Clinton, Obama, celebs to join Biden in NYC for fundraising event

    01:55
  • NTSB recovers cargo ship's voice data recorder, interviews crew

    02:49
  • How this longtime apothecary in NYC looks toward the future

    04:31
  • Browse these flavorful products from trailblazing women

    04:23
  • McDonald’s to add Krispy Kreme doughnuts to the menu

    01:02
  • Mega Millions ticket worth $1.1 billion sold in New Jersey

    00:47
  • Evan Gershkovich’s parents remain hopeful for his release

    01:20
  • Key Bridge collapse: NTSB recovers ship’s voyage data recorder

    01:50
  • New York Red Bull players give their coats to kids during heavy rain

    00:41
  • Inside the heavy security measures ahead of Paris Olympics

    03:35

Pfizer executive: ‘We’re confident’ about our vaccine being safe and effective for kids

04:44

Dr. Bill Gruber, Pfizer’s senior vice president of vaccine clinical research and development as well as a pediatrician, joins TODAY to talk about new data released from Pfizer showing its vaccine to be safe and effective for kids between 5 and 11. He says, “We intend to submit the data [to the FDA] by the end of the month.” He adds, “We’re hopeful and expectant that the FDA will approve the vaccine based on the data we have.” He also discusses an FDA panel’s recommendations about a third booster shot for adults.